The investigation centers on the company’s April 29, 2026, disclosure of first-quarter financial results. During the earnings call, management revealed that profit margins suffered due to a recall involving a pharmaceutical diagnostics supplier and declines in the Patient Care Solutions segment. These factors forced the company to slash its full-year 2026 adjusted earnings per share guidance to a range of $4.80 to $5.00, down from the previously stated $4.95 to $5.15.

Investors reacted sharply to the news, driving the stock down $9.01 to close at $59.49. Glancy Prongay Wolke & Rotter LLP is now seeking information from shareholders who suffered losses during this period to determine if federal securities laws were violated. The firm is also soliciting potential whistleblowers who may possess non-public information concerning the company's internal operations or the nature of the supply chain issues cited during the Q1 report.